Spotlight on Dr. Simon Turcotte, Research Fellow of the Institute and one of the 3 scientists from the Pan-Canadian Project, Canadian Cholangiocarcinoma Collaborative (C3).
They launched this new research project with a $7.4 million grant from the Canadian Cancer Society and the Canadian Institutes of Health Research.
With this funding, C3 scientists will plan a clinical trial of tumour-infiltrating lymphocyte (TIL) immunotherapy for 15 cholangiocarcinoma patients, a first in Canada for this type of cancer.
To read the full article, click here.
Other news
![Personalized cellular immunotherapy: Dr. Simon Turcotte, one of the three principal scientists of a pan-Canadian project](https://www.icm.qc.ca/wp-content/uploads/2020/11/istock-1044233084-1600x1600.jpg)
Subscribe to our newsletter
Thank you, we have received your registration
Sorry, an error occurred
![](https://www.icm.qc.ca/wp-content/themes/icm/assets/img/ajax-loader.gif)